Neurodyn Acquires Memogain® for Dementia in Alzheimer’s Disease

CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany (galantos.com) all assets related to their Alzheimer’s prescription drug candidate – Memogain®. Memogain® has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

Help employers find you! Check out all the jobs and post your resume.